A 24-month real life PErsistence efficacy and safety study in IBD patients in REMission switched from intravenous infliximab to subcutaneous infliximab CT-P13 Remsima®SC The PEREM study 24-month French multicentre, observational, prospective cohort study
Investigateurs
- Dr Nicolas MATHIEU
La fiche complète est accessible aux membres du GETAID.
Se connecter